Abstract
Background Limited recent data exist on prescribing patterns and patient characteristics for glucagon-like peptide 1 receptor agonists (GLP-1 RAs), an important drug class used as anti-diabetic medication (ADM) for patients with type 2 diabetes mellitus (T2D) and/or anti-obesity medication (AOM) in patients with overweight or obesity.
For brevity, we use the term GLP-1 RA to refer to both GLP-1 RA and dual GLP-1 RA/GIP medications.
Objective To describe recent trends in prescribing and dispensing of GLP-1-based medications in the US.
Methods Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provide more than 18% of all daily clinical care in the US, we identified people who were prescribed a GLP-1-based medication between January 01, 2018 and June 30, 2024. We describe prescribing volumes and patient characteristics over time, by medication, and by FDA-labeled use. Among the subset of patients for whom post-prescription dispensing data is available, we describe the proportion and characteristics of patients who were and were not dispensed a GLP-1 RA following their prescription.
Results 1,162,662 patients were prescribed a GLP-1 RA between January 2018 and June 2024, with 4,815,135 total prescriptions during this period. Among first-time prescriptions for which use could be established, ADMs accounted for 83.0% and AOMs accounted for 17.0%. The most common first-time medication was semaglutide (n = 644,272). Among those with available data, 70.0% of first-time ADM prescriptions overall and 73.7% in March 2024 had a fill within 60 days. By comparison, 43.6% of first-time AOM prescriptions overall and 47.2% in March 2024 had a fill within 60 days.
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2024 increased slightly relative to March 2024 (+8.43%).
Month-over-month ADM prescribing increased in April and May 2024 then decreased slightly in June 2024. ADM prescribing in June 2024 remained approximately the same as March 2024 (+0.92%).
Among ADMs, semaglutide was the most prescribed medication. In late 2023, tirzepatide surpassed dulaglutide as the second most commonly prescribed ADM.
AOM prescribing increased in June 2024 compared to March 2024 (+27.1%)
Semaglutide was the most commonly prescribed AOM, followed by AOM tirzepatide. Prescribing of AOM tirzepatide was observed in the first month of availability in pharmacies, December 2023.
First-time prescribing rates (first-time GLP-1 RA prescriptions per total prescriptions) in June 2024 were slightly lower than rates in March 2024 (−6.90%).
First-time prescribing of ADMs decreased in June 2024, relative to March 2024 (−19.71%).
First-time prescribing of AOMs increased slightly in June 2024, compared to March 2024 (+7.26%).
While overall prescribing of semaglutide increased throughout second quarter of 2024, first-time prescribing of semaglutide slowed from 0.9% of prescriptions in May 2024 to 0.7% in June 2024. Similar declines were observed for ADM, AOM, and unknown semaglutide. New prescribing of tirzepatide decreased in each of the 3 months over the last quarter.
During the full time period, 73.7% of GLP-1 RA prescriptions had a dispense within 60 days of their prescription (e.g., were initiated within 60 days).
For patients first prescribed an ADM in March 2024, 73.7% filled a GLP-1 RA within 60 days. Initiation rates for ADM GLP-1 RA increased slightly in March 2024, relative to December 2023 (+1.72%).
For patients first prescribed an AOM in March 2024, 47.2% filled a GLP-1 RA within 60 days. Initiation rates for AOM GLP-1 RA increased substantially in March 2024, relative to December 2023 (+41.41%).
About this report This report provides recent trends in the prescribing and dispensing of glucagon-like peptide-1 receptor agonist (GLP-1 RAs)-based medications, including dual GLP-1 RA/gastric inhibitory polypeptide (GIP) over time, by medication, and by FDA-labeled use. We used near real-time, aggregated electronic health record (EHR) data from a collective of US healthcare systems to describe prescribing and dispensing of GLP-1 RA medications from January 2018 to June 2024.
Competing Interest Statement
All authors are employees of Truveta, Inc.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Normalized electronic health record data are de-identified by expert determination under the HIPAA Privacy Rule before being made available to researchers. In accordance with 45 C.F.R. Paragraph 46.101 Protection of Human Subjects, our study did not require Institutional Review Board approval because it used only deidentified medical records. All data used in this study are publicly available to Truveta subscribers and may be accessed at studio.truveta.com.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Denotes co-first author
The data has been updated till June 2024
Data Availability
The data used in this study are available to all Truveta subscribers and may be accessed at studio.truveta.com.
